SARS-CoV-2 variants of concern, variants of interest and lineage A.27 are on the rise in Côte d'Ivoire

Etilé Augustin Anoh^{1,*}, Grit Schubert^{2,*}, Oby Wayoro¹, Monemo Pacôme^{1,3}, Essia Belarbi², Andreas Sachse², Sébastien Calvignac-Spencer², Fabian Leendertz², Bamourou Diané & Chantal Akoua-Koffi^{1,3}

Affiliations

¹ Centre Hospitalier Universitaire Bouaké, Côte d'Ivoire

² Robert Koch-Institute, Berlin, Germany

³ Université Alassane Ouattara de Bouaké, Côte d'Ivoire

* these authors contributed equally to this work

Correspondence: anohethyl@yahoo.fr, schubertg@rki.de, CalvignacS@rki.de,

cakoua26@gmail.com

Keywords

SARS-CoV-2, VOC, VOI, whole genome sequencing, ARTIC protocol, sub-Saharan Africa

Abstract

SARS-CoV-2 variants of concern (VOC) and variants of interest (VOI) are heavily altering the COVID-19 pandemic's course due to their increased transmissibility, virulence and immune escape abilities. Data on their spread in western sub-Saharan Africa is however still scarce. We therefore sequenced viral genomes from SARS-CoV-2 cases identified in central and

northern Côte d'Ivoire between May 2020 and March 2021. We report the introduction of VOC B.1.1.7 as early as mid-January 2021, followed by detection of a single case of VOC B.1.351, as well as VOI B.1.525. Since early 2021 VOC/VOI are gradually dominating the SARS-CoV-2 virus pool in Côte d'Ivoire, as seen in other regions of the world. Intriguingly, we also find that another lineage, A.27, has also been on the rise over the same period. In sum, this study highlights again the extremely rapid local diffusion of VOC, VOI and possibly A.27, and the importance of further reinforcing capacities for genomic surveillance on the African continent.

Competing interests

The authors declare that they have no competing interests.

Funding

The study is funded by two grants from the German Federal Ministry of Education and Research (BMBF; grant number 01KA1606; grant number 01KI2047). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Main Text

The ongoing SARS-CoV-2 pandemic is coined by the emergence and spread of viral lineages with increased transmissibility, virulence and immune escape abilities, the variants of concern [VOC; (1, 2)]. Since end-2020, three VOC - B.1.1.7 which originated in the U.K (20I/501Y.V1), B.1.351 (20H/501Y.V2) from South Africa, and P.1 (20J/501Y.V3) from Brazil - have shown sustained regional community transmission followed by quick international

49 dispersal. B.1.1.7 is now on the verge to becoming the dominant lineage worldwide. The
50 ramping up of genomic surveillance on a global scale has also resulted in the identification of
51 other variants presenting mutations potentially associated with altered phenotypes but not
52 yet formally identified as exhibiting altered properties, the variants of interest [VOI; (2)]. As
53 of March 30th, WHO has identified 6 VOI associated to local community transmission and
54 some degree of international spread (1).
55 SARS-CoV-2 genomic data have accumulated at very different paces in different regions of
56 the world and West Africa is among the least covered [see (3, 4) and references therein]. In
57 order to shed light on the evolution and spread of SARS-CoV-2 and its VOC/VOI in this
58 region, we sequenced viral genomes from cases identified in central and northern Côte
59 d'Ivoire between May 2020 and March 2021.

60 **Rapid lineage turn-over to VOC/VOI in central Côte d'Ivoire**

61 We obtained nucleic acids extracted from naso/oropharyngeal specimens from the national
62 SARS-CoV-2 surveillance program. Those samples had been tested positive for SARS-CoV-2
63 by real-time PCR. Between May 23rd 2020 and March 9th 2021, 2637 naso/oropharyngeal
64 specimens from COVID-19 suspect cases had been received by the Centre Hospitalier
65 Universitaire (CHU) Bouaké, of which 524 specimens tested positive for SARS-CoV-2. An
66 additional 8 SARS-CoV-2 positive nucleic acids were obtained from a running surveillance
67 study on acute respiratory infections in the Bouaké region and western Côte d'Ivoire [N_{tested}
68 = 828; (5)].

69 We generated complementary DNA (cDNA) and performed on-site whole genome
70 sequencing at the CHU Bouaké by applying the multiplex PCR approach described in the
71 ARTIC protocol (6) and sequencing the resulting amplicons on a MinION device (Oxford
72 Nanopore Technologies). We also followed the ARTIC protocol for genome consensus

sequence generation (7). Genomes were assigned to viral lineages using pangolin [version 2.3.8, April 2nd 2021; (8)]. Lastly, we also performed additional phylogenetic analyses aimed at refining the placement/lineage assignment of 5 genomes initially assigned to lineage A, of which 4 genomes fell into A.27 diversity and where reassigned accordingly (Supplementary Figure 1). A total of 166 SARS-CoV-2 genomes were generated, spanning the period from May 2020 to March 2021.

From May 2020 to December 2020, we detected 20 pango lineages, with lineage A.19 being by far the dominant one, followed by A.18 and B.1 (Figure 1A and B). From January 2021 on, the distribution of viral lineages changed drastically (Figure 1C). We detected 2 VOCs, B.1.1.7 (first detection January 15th 2021) and B.1.351 (a single detection on March 6th 2021), and one VOI, B.1.525 (first detection February 8th 2021). The frequency of VOC/VOI gradually increased from January to March (Figure 1D – F), leading to a rapid replacement of previously circulating lineages. In March 2021, VOC/VOI altogether represented 67% of sequenced genomes (Figure 1F).

Emergence and rise of lineage A.27

The emergence of VOC/VOI was accompanied by the appearance and increasing frequency of lineage A.27 (29 % of genomes from January to March 2021; Figure 1D - F). As a number of VOC/VOI do, A.27 harbours many lineage defining mutations [n=18; (9)]. A.27 genomes are characterized by a S:614D background and show four coding mutations in spike potentially linked to increased transmissibility or immune escape [S:L18F, S:L452R, S:N501Y and S:H655Y; (10-12)]. This lineage was initially defined following an outbreak in Mayotte, a French overseas territory and island in the Mozambique Channel (13). As of April 1st 2021, a mere 226 A.27 genomes have been published on the GISAID database, primarily from European countries (14). A.27 was first detected in December 2020 in Denmark but the high

proportion of those genomes appearing in France/Mayotte (144 genomes) might pinpoint a potential origin or early elevated spread of the variant in this country. While prior to this study only three A.27 genomes had been reported from continental sub-Saharan Africa (two from Nigeria, one from Rwanda), our results show that that this lineage probably dispersed much more broadly on the continent.

Limitations of the study

The data presented here are geographically limited to central and northern Côte d'Ivoire and might thus only reflect local outbreak patterns. VOC/VOI/A.27 were probably imported via travellers but the very uneven international sampling prevents firmly determining the origins of importation. Potential epidemiological links to southern Côte d'Ivoire, where Abidjan acts as the main country's hub for international travel, should be investigated to better understand within country spread.

Conclusions

The data presented here highlight again the extremely rapid local diffusion of VOC, VOI and, possibly, A.27. Monitoring the spread and possibly local emergence of variants provides information that can guide governmental measures towards pandemic control. In the next few months, reinforcing genomic surveillance on the continent will be a major regional and global task.

Ethics approval

The study adheres to the tenets of the Declaration of Helsinki and national ethical and legislation standards. The CHU Bouaké laboratory is part of the national surveillance programme for SARS-CoV-2 diagnosis in Côte d'Ivoire. Approval by institutional ethics committees for conducting the ANDEMIA surveillance study was given by the Comité

National d’Ethique des Sciences de la Vie et de la Santé de Côte d’Ivoire (ethics permit number 105/MSHP/CNER-dk), and by the Ethikkommission - Ethikausschuss am Campus Virchow-Klinikum, Charité, Germany (ethics permit number EA2/230/17)]. The study objectives were explained by trained surveillance officers, and informed written consent for participating in the study was collected from all participants. Written consent was obtained by parents or legal guardians of minors. Personal patient identifiers were not accessible to the authors. Inclusion of SARS-CoV-2 diagnostics into the study was granted by the Comité National d’Ethique des Sciences de la Vie et de la Santé de Côte d’Ivoire (ethics permit number 073-20/MSHP/CNESVS-kp).

Authors' contributions

All authors made substantial contributions towards the conduct of the study. CAK, EB, FL, GS designed the study. CAK and BD guaranteed study implementation in Côte d’Ivoire. EB, GS and SCS were driving the development of methodologies and analyses. AS, EAA, GS, MP, OW and SCS performed analyses. EAA, GS and SCS drafted the manuscript. All authors revised earlier versions of the manuscript and approved the final version for submission.

Informed consent

Suspect cases of COVID-19 were tested for SARS-CoV-2 during clinical routine, following national testing guidelines. Patients were aware of the testing and consented to the sampling of respiratory specimens.

Data availability

All SARS-CoV-2 sequences generated at CHU Bouaké, Côte d’Ivoire, are available on GISAID.

145

146 Acknowledgements

147 We are grateful to S. Tomczyk, T. Eckmanns, K. Nowak, P. Pitzinger, S. Kribi and R. Wood for
148 their participation in the development and implementation of the broader study idea, and
149 Caroline Röthemeier and Kevin Merkel for technical support (all Robert Koch-Institute). At
150 Côte d'Ivoire, we thank Prof. M. Dosso, director of the Institut Pasteur of Côte d'Ivoire and
151 national coordinator of COVID-19 laboratory activities, for including CHU Bouaké into
152 respective activities and granting permission to sequencing tested specimens. We further
153 wish to acknowledge Dr. F. Bamba-Touré, the regional director of health at the Ministry of
154 Health, as well as Dr. M. Coulibaly at the Institut National d'Hygiène Publique for facilitating
155 the conduct of the study. Lastly, we extend our thanks to the local SARS-CoV-2 surveillance
156 team of Dr. M. Soundélé, Dr. L. Karidioula, Dr. P. Ouattara, Dr. I. Dembélé, N. Wohi and S.
157 Karidiouala for their efforts in implementing the testing of respiratory specimens for SARS-
158 CoV-2 at CHU Bouaké.

159 We thank the funding body that made this study possible, the German Federal Ministry of
160 Education and Research (BMBF; grant number 01KA1606 and grant number 01KI2047).

161

162 References

- 163 1. World Health Organization. COVID-19 weekly epidemiological update, 30 March
164 2021. 2021.
- 165 2. World Health Organization. COVID-19 weekly epidemiological update, 25 February
166 2021. 2021.
- 167 3. Otu A, Agogo E, Ebenso B. Africa needs more genome sequencing to tackle new
168 variants of SARS-CoV-2. Nature Medicine. 2021:1-2.

- 169 4. Inzaule SC, Tessema SK, Kebede Y, Ouma AEO, Nkengasong JN. Genomic-informed
170 pathogen surveillance in Africa: opportunities and challenges. The Lancet Infectious
171 Diseases. 2021.
- 172 5. African Network for improved Diagnostics, Epidemiology and Management of
173 Common Infectious Agents – ANDEMIA 2018 [Available from: <https://www.andemia.org/>.
- 174 6. Tyson JR, James P, Stoddart D, Sparks N, Wickenhagen A, Hall G, et al. Improvements
175 to the ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore.
176 bioRxiv : the preprint server for biology. 2020:2020.09.04.283077.
- 177 7. Loman N, Rowe W, Rambaut A. nCoV-2019 novel coronavirus bioinformatics protocol
178 2020 [Available from: <https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html>.
- 179 8. O'Toole Á, Scher E, Underwood A, Jackson B, Hill V, McCrone J, et al. Pangolin: lineage
180 assignment in an emerging pandemic as an epidemiological tool. 2020.
- 181 9. Pango lineages. Lineage A.27 2021 [Available from: [https://cov-](https://cov-lineages.org/lineages/lineage_A.27.html)
182 [lineages.org/lineages/lineage_A.27.html](https://cov-lineages.org/lineages/lineage_A.27.html).
- 183 10. McCallum M, De Marco A, Lempp FA, Tortorici MA, Pinto D, Walls AC, et al. N-
184 terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell. 2021.
- 185 11. Nelson G, Buzko O, Spilman PR, Niazi K, Rabizadeh S, Soon-Shiong PR. Molecular
186 dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the
187 combination of E484K, K417N and N501Y mutations (501Y. V2 variant) induces
188 conformational change greater than N501Y mutant alone, potentially resulting in an escape
189 mutant. BioRxiv. 2021.
- 190 12. Tchesnokova V, Kulakesara H, Larson L, Bowers V, Rechkina E, Kisiela D, et al.
191 Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers
192 recent massive expansion of SARS-Cov-2 variants. bioRxiv. 2021:2021.02.22.432189.

13. Simon-Lorier E. Potential new lineage causing a cluster in Mayotte 2021 [Available from: <https://github.com/cov-lineages/pango-designation/issues/11>.

14. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative contribution to global health. *Global Challenges*. 2017;1(1):33-46.

15. Tennekes M. Treemap: Treemap Visualization. R package version 2.4-2. ed2017.

Figure legends

Figure 1. Distribution of SARS-CoV-2 lineages among 166 genomes sequenced at the Centre Hospitalier Universitaire Bouaké in Côte d'Ivoire. Data were subdivided into sample collection periods: A) May – July 2020, B) August – December 2020, C) January – March 2021, D) January 2021, E) February 2021, F) March 2021. Viral lineage assignment was conducted using pangolin [version 2.3.8, April 2nd 2021; (6)]. The treemap plot was drawn with R, package treemap (15).